Development and validation of a new bioanalytical method for quantification of CDK4/6 inhibitor in Spiked Human Plasma by HPLC-UV
References
- DiPippo AJ, Patel NK, Barnett CM. Cyclin‐dependent kinase inhibitors for the treatment of breast cancer: past, present, and future. Pharmacotherapy. 2016;36(6):652-67.
- Cha C, Ahn SG, Yoo TK, Kim KM, Bae SJ, Yoon C, et al. Local treatment in addition to endocrine therapy in hormone receptor-positive and HER2-negative oligometastatic breast cancer patients: a retrospective multicenter analysis. Breast Care. 2020;15(4):408-14.
- Barroso-Sousa R, Shapiro GI, Tolaney SM. Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer. Breast Care. 2016;11(3):167-73.
- Curigliano G, Pardo PG, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. The Breast. 2016;28:191-8.
- Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, et al. A phase I study of the CDK4/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors. Clin Cancer Res. 2017;23(10): 2433-41.
- Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. The Lancet. 2020;395(10226):817-27.
- Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93-115.
- Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672-7.
- Suárez-Arroyo IJ, Loperena-Alvarez Y, Rosario-Acevedo R, Martínez-Montemayor MM. Ganoderma spp.: a promising adjuvant treatment for breast cancer. Medicines. 2017;4(1):15.
- Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors Mechanism of Action and Clinical Impact of Ribociclib. Clin Cancer Res. 2017; 23(13):3251-62.
- Verheijen RB, Yu H, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017; 102(5):765-76.
- van Nuland M, Rosing H, Schellens JH, Beijnen JH. Bioanalytical LC–MS/MS validation of therapeutic drug monitoring assays in oncology. Biomed Chromatogr. 2020;34(1):e4623.
- Posocco B, Buzzo M, Poetto AS, Orleni M, Gagno S, Zanchetta M, et al. Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. PloS One. 2020;15(2):e0228822.
- Bao X, Wu J, Sanai N, Li J. Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry. J Pharm Biomed Anal. 2019;166:197-204.
- Braal CL, Lam MH, Rienks T, van Tilborg CJ, Heuts W, Heijns JB, et al. Quantification of ribociclib in dried blood spots by LC–MS/MS: Method development and clinical validation. J Pharm Biomed Anal. 2021;201:114118.
- Turković L, Bočkor L, Ekpenyong O, Silovski T, Lovrić M, Crnković S, et al. Development and validation of a novel LC-MS/MS method for the simultaneous determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A prerequisite for personalized breast cancer treatment. Pharmaceuticals. 2022;15(5):614.
- Kamble SN, Munipalli VK, Talapadatur H, Singh RM, Warde S, Nayak S, et al. Development and validation of novel HPLC method for analytical evaluation of Lemborexant in tablet dosage form. GSCARR. 2022;11(1):132-43.
- Meesters R, Voswinkel S. Bioanalytical method development and validation: from the USFDA 2001 to the USFDA 2018 guidance for industry. J Appl Bioanal. 2018;4 (3):67-73.
- Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation, Department of Health & Human Services. 2001:4-10. [ http://www.labcompliance.de/documents/FDA/FDA-Others/Laboratory/f-507bioanalytical-4252fnl.pdf].
Language: English
Page range: 81 - 86
Submitted on: Dec 12, 2022
Accepted on: Jan 8, 2023
Published online: Jun 30, 2023
Published in print: Jun 1, 2023
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Related subjects:
© 2023 Rakesh U. Shelke, Dinesh D. Rishipathak, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.